AZD-1940

AZD-1940 is an orally active small molecule drug developed by AstraZeneca as a peripherally selective cannabinoid receptor agonist. It binds with high affinity to both the cannabinoid CB1 and CB2 receptors (pKi values of 7.93 for CB1 and 9.06 for CB2) and was designed to provide analgesic effects without central nervous system side effects by limiting its action to peripheral tissues. Despite promising preclinical results in animal models of pain, clinical trials in humans failed to demonstrate sufficient analgesic efficacy and revealed unexpected central side effects such as mild-to-moderate CNS-related symptoms. As a result, development of AZD-1940 for neuropathic pain and other indications was discontinued[1][2][6].

Other names

Ethanesulfonamide N-(1-((4,4-difluorocyclohexyl)methyl)-2-(1,1-dimethylethyl)-1H-benzimidazol-5-yl)